↓ Skip to main content

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line

Overview of attention for article published in Frontiers in oncology, June 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
1 X user
patent
2 patents

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
Published in
Frontiers in oncology, June 2014
DOI 10.3389/fonc.2014.00157
Pubmed ID
Authors

Abdulaziz Al-Farsi, Peter Michael Ellis

Abstract

Historically, the treatment algorithm applied to non-small cell lung cancer (NSCLC) was the same for all histologic subtypes. However, recent advances in our understanding of the molecular profiles of squamous and non-squamous NSCLC have changed this perspective. Histologic subtype and the presence of specific molecular abnormalities have predictive value for response to and toxicity from therapy, as well as overall survival. For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. The role of epidermal growth factor receptor monoclonal antibodies is uncertain. Maintenance therapy is not widely recommended, although data exist for the use of erlotinib. The standard recommendation for second-line therapy is docetaxel and erlotinib should be considered as second or third-line therapy. There is ongoing research identifying molecular targets in squamous NSCLC and many agents are in early phase clinical trials. Immunotherapeutic approaches targeting programed death-1 receptor and its ligand (PD-L1) appear promising.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 1 2%
Unknown 61 98%

Demographic breakdown

Readers by professional status Count As %
Other 14 23%
Researcher 8 13%
Student > Bachelor 8 13%
Student > Master 6 10%
Student > Ph. D. Student 6 10%
Other 13 21%
Unknown 7 11%
Readers by discipline Count As %
Medicine and Dentistry 24 39%
Biochemistry, Genetics and Molecular Biology 8 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Immunology and Microbiology 4 6%
Agricultural and Biological Sciences 4 6%
Other 9 15%
Unknown 8 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2020.
All research outputs
#8,270,860
of 25,394,764 outputs
Outputs from Frontiers in oncology
#3,082
of 22,440 outputs
Outputs of similar age
#76,519
of 242,642 outputs
Outputs of similar age from Frontiers in oncology
#20
of 99 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 22,440 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,642 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.